A STING-activating nanovaccine for cancer immunotherapy

Nature Nanotechnology

Volumn 12, Issue 7, 2017, Pages 648-654

  Luo, Min ^a   Wang, Hua ^b   Wang, Zhaohui ^a   Cai, Haocheng ^b   Lu, Zhigang ^b   Li, Yang ^a   Du, Mingjian ^b   Huang, Gang ^a   Wang, Chensu ^a   Chen, Xiang ^b   Porembka, Matthew R ^a   Lea, Jayanthi ^a   Frankel, Arthur E ^a   Fu, Yang Xin ^a   Chen, Zhijian J ^b   Gao, Jinming ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; ANTIGENS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; GENES; GLYCOPROTEINS; T-CELLS; VIRUSES;

ANTIGEN PRESENTING CELLS; CANCER IMMUNOTHERAPY; CYTOKINE EXPRESSION; HUMAN PAPILLOMA VIRUS; POLYMERIC NANOPARTICLES; SIGNALLING PROTEINS; TOLL-LIKE RECEPTORS; TYPE I INTERFERONS;

TUMORS;

CANCER VACCINE; CD86 ANTIGEN; CYTOKINE; MITOCHONDRIAL ANTIVIRAL SIGNALLING PROTEIN; MITOCHONDRIAL PROTEIN; PC7A NANOVACCINE; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; IPS-1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NANOPARTICLE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESPONSE; GENE; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STING GENE; TUMOR IMMUNITY; ANIMAL; CELLULAR IMMUNITY; CHEMISTRY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; PATHOLOGY; THP-1 CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NANOPARTICLES; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; THP-1 CELLS;

EID: 85018382461     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2017.52     Document Type: Article

References (41)

1. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68 (2015).
2. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
3. Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489-496 (2017).
4. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519-522 (2014).
5. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159-1164 (2007).
6. Ma, X. et al. Ultra-pH-sensitive nanoprobe library with broad pH tunability and fluorescence emissions. J. Am. Chem. Soc. 136, 11085-11092 (2014).
7. Wang, C. et al. A nanobuffer reporter library for fine-scale imaging and perturbation of endocytic organelles. Nat. Commun. 6, 8524 (2015).
8. Boussif, O. et al. Aversatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297-7301 (1995).
9. Maldonado, R. A. et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl Acad. Sci. USA 112, E156-E165 (2015).
10. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
11. Hemmi, H. et al. A toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
12. + dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
13. Heath, W. R. et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004).
14. Wilson, J. T. et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7, 3912-3925 (2013).
15. Wang, Z. et al. A redox-activatable fluorescent sensor for the high-throughput quantification of cytosolic delivery of macromolecules. Angew. Chem. Int. Ed. 56, 1319-1323 (2017).
16. Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K. & Escors, D. Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. Immunol. Endocr. Metab. Agents Med. Chem. 12, 224-235 (2012).
17. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405-414 (2015).
18. Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67-73 (2013).
19. Trinchieri, G. Type I interferon: friend or foe? J. Exp. Med. 207, 2053-2063 (2010).
20. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738 (2001).
21. Baccala, R., Hoebe, K., Kono, D. H., Beutler, B. & Theofilopoulos, A. N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 13, 543-551 (2007).
22. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786-791 (2013).
23. Carroll, E. C. et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44, 597-608 (2016).
24. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842 (2014).
25. Lemos, H., Huang, L., McGaha, T. L. & Mellor, A. L. Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur. J. Immunol. 44, 2847-2853 (2014).
26. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
27. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
28. Sun, Y. Y. et al. Local HPV recombinant vaccinia boost following priming with an HPV DNAvaccine enhances local HPV-specific CD8+ T cell mediated tumor control in the genital tract. Clin. Cancer Res. 22, 657-669 (2016).
29. Liu, Z., Zhou, H., Wang, W., Fu, Y. X. & Zhu, M. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. Oncoimmunology 5, e1147641 (2016).
30. Rice, A. E. et al. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene. Ther. 22, 454-462 (2015).
31. Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389-1402 (2013).
32. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
33. Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205-214 (2015).
34. Zhou, K. et al. Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew. Chem. Int. Ed. 50, 6109-6114 (2011).
35. Zhou, K. et al. Multi colored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. J. Am. Chem. Soc. 134, 7803-7811 (2012).
36. Tsarevsky, N. V. & Matyjaszewski, K. 'Green' atom transfer radical polymerization: from process design to preparation of well-defined environmentally friendly polymeric materials. Chem. Rev. 107, 2270-2299 (2007).
37. Li, X. D. et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390-1394 (2013).
38. Collins, A. C. et al. Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis. Cell Host Microbe. 17, 820-828 (2015).
39. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226-235 (2013).
40. Huang, L. et al. Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J. Immunol. 188, 4913-4920 (2012).
41. Hoshi, M. et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J. Immunol. 185, 3305-3312 (2010).